Replies to post #146 on Clinuvel Pharmaceuticals (CLVLY)

[FarmaZutical]

Hi,

You're right. We need to look at PACME. Price after cost and marketing expenses.

But marketing and distribution is very cheap for the company. They more or less know all the patients, doctors and the porphyria centers by name.

But you're right. We need to subtract expenses. Still, there is room for some explosive price action in the near future.

At this point it seems that Vitiligo and label extensions are not even prices in.